phosphorylethanolamine has been researched along with Arteriosclerosis in 1 studies
phosphorylethanolamine: RN given refers to parent cpd; structure
O-phosphoethanolamine : The ethanolamine mono-ester of phosphoric acid, and a metabolite of phospholipid metabolism. This phosphomonoester shows strong structural similarity to the inhibitory neurotransmitter GABA, and is decreased in post-mortem Alzheimer's disease brain.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ravandi, A | 1 |
| Kuksis, A | 1 |
| Shaikh, NA | 1 |
1 other study available for phosphorylethanolamine and Arteriosclerosis
| Article | Year |
|---|---|
Glucosylated glycerophosphoethanolamines are the major LDL glycation products and increase LDL susceptibility to oxidation: evidence of their presence in atherosclerotic lesions.
Topics: Arteriosclerosis; Ethanolamines; Glycosylation; Humans; Lipoproteins, LDL; Male; Oxidation-Reduction | 2000 |